Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., filed a statement of changes in beneficial ownership on November 10, 2026, reporting a purchase of common stock on November 9, 2026.

Key Highlights

  • Reporting person: Thomas K. Equels, identified as Director, CEO, and President of AIM ImmunoTech Inc.
  • Transaction: Purchase (code P) of 31,298 shares of common stock on November 9, 2026.
  • Price per share: $0.162, as reported in the filing.
  • Post-transaction ownership: Equels directly held 254,095 shares of common stock following the transaction.
  • No derivative securities: Table II of the filing contains no reported derivative transactions.

Equels Adds to Direct Common Stock Position at $0.162 Per Share

According to the filing, Thomas K. Equels acquired 31,298 shares of AIM ImmunoTech Inc. common stock on November 9, 2026, at a price of $0.162 per share. The transaction is coded "P," indicating an open-market purchase. Following the transaction, the filing reports Equels directly owned 254,095 shares of common stock in the company. The filing was signed by Equels and submitted on November 10, 2026.

AIM ImmunoTech Inc. is listed on NYSE American under the ticker symbol AIM, as stated in the filing's issuer section. The company is a biopharmaceutical firm focused on immunology and oncology, as reflected in its name and public disclosures. Equels holds dual roles at the company, serving as both a director and as CEO and President, as indicated in the relationship section of the filing. The filing was submitted by one reporting person and covers only non-derivative securities; Table II, which covers derivative instruments such as options and warrants, reflects no activity for this reporting period.

The filing states no deemed execution date separate from the transaction date of November 9, 2026, and indicates the ownership form for the reported shares is direct. No indirect beneficial ownership entries appear in the filing for this transaction.

What Was Disclosed

The filing disclosed that Thomas K. Equels, CEO, President, and Director of AIM ImmunoTech Inc. (NYSE American:AIM), purchased 31,298 shares of common stock on November 9, 2026, at $0.162 per share, bringing his direct holdings to 254,095 shares.